{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:24:02Z","timestamp":1787228642374,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017291","name":"Zhongshan Science and Technology Bureau","doi-asserted-by":"publisher","award":["2021B1017"],"award-info":[{"award-number":["2021B1017"]}],"id":[{"id":"10.13039\/501100017291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010883","name":"Traditional Chinese Medicine Bureau of Guangdong Province","doi-asserted-by":"publisher","award":["20202258"],"award-info":[{"award-number":["20202258"]}],"id":[{"id":"10.13039\/501100010883","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tranon.2026.102894","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:54:37Z","timestamp":1784537677000},"page":"102894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["ATO alleviates T-cell immunosuppression by inducing apoptosis-associated secretion of IL-2 in FLT3-ITD-mutated acute myeloid leukemia"],"prefix":"10.1016","volume":"71","author":[{"given":"Yiqing","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102894_bib0001","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","article-title":"Acute myeloid leukaemia","volume":"368","author":"Estey","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2026.102894_bib0002","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2026.102894_bib0003","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tranon.2026.102894_bib0004","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102894_bib0005","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"AML Study Group Ulm. Acute myeloid leukemia, prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm","volume":"100","author":"Fr\u00f6hling","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102894_bib0006","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102894_bib0007","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1038\/s41467-022-31489-9","article-title":"Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3\/ITD allelic ratios","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102894_bib0008","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tranon.2026.102894_bib0009","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1158\/1078-0432.CCR-13-2052","article-title":"Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies","volume":"20","author":"Zhang","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102894_bib0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-018-0675-4","article-title":"FLT3 inhibitors in acute myeloid leukemia","volume":"11","author":"Wu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2026.102894_bib0011","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1158\/0008-5472.CAN-16-2593","article-title":"Adaptation to TKI treatment reactivates ERK signaling in tyrosine kinase-driven leukemias and other malignancies","volume":"77","author":"Bruner","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102894_bib0012","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2026.102894_bib0013","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.2022.14578","article-title":"Diagnosis and treatment of myelodysplastic syndromes: a review","volume":"328","author":"Sekeres","year":"2022","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.tranon.2026.102894_bib0014","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2020008477","article-title":"Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia","volume":"138","author":"Han","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102894_bib0015","unstructured":"Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma - PubMed, (n.d.). https:\/\/pubmed.ncbi.nlm.nih.gov\/38684648\/(accessed June 5, 2025)."},{"key":"10.1016\/j.tranon.2026.102894_bib0016","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/ijc.21557","article-title":"Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas","volume":"118","author":"Luo","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102894_bib0017","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41416-024-02880-8","article-title":"Low-dose arsenic trioxide inhibits pancreatic stellate cell activation via LOXL3 expression to enhance immunotherapy in pancreatic cancer","volume":"131","author":"Zhao","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102894_bib0018","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrm3979","article-title":"Regulation of RAF protein kinases in ERK signalling","volume":"16","author":"Lavoie","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.tranon.2026.102894_bib0019","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/hon.3076","article-title":"DNA damage accumulation and repair defects in FLT3-ITD acute myeloid leukemia: implications for clonal evolution and disease progression","volume":"41","author":"Lagunas-Rangel","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.tranon.2026.102894_bib0020","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.3390\/cancers12123511","article-title":"Pan-RAF inhibition shows anti-leukemic activity in RAS-mutant acute myeloid leukemia cells and potentiates the effect of Sorafenib in cells with FLT3 mutation","volume":"12","author":"Khoury","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.102894_bib0021","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/sj.leu.2403859","article-title":"Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia","volume":"19","author":"Ricciardi","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102894_bib0022","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.ccell.2024.10.014","article-title":"Interleukin-1\u03b1 release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity","volume":"42","author":"H\u00e4nggi","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2026.102894_bib0023","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1749-6632.1993.tb35923.x","article-title":"The interleukin-2 receptor: a target for immunotherapy","volume":"685","author":"Waldmann","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.tranon.2026.102894_bib0024","doi-asserted-by":"crossref","first-page":"11925","DOI":"10.1128\/JVI.79.18.11925-11934.2005","article-title":"Aberrant activation of the interleukin-2 autocrine loop through the nuclear factor of activated T cells by nonleukemogenic human T-cell leukemia virus type 2 but not by leukemogenic type 1 virus","volume":"79","author":"Niinuma","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.tranon.2026.102894_bib0025","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tranon.2026.102894_bib0026","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3324\/haematol.10802","article-title":"Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen","volume":"92","author":"Mathews","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.tranon.2026.102894_bib0027","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3109\/10428194.2013.842985","article-title":"Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype","volume":"55","author":"Poir\u00e9","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.tranon.2026.102894_bib0028","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/leu.2016.122","article-title":"PML-RAR\u03b1 kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy","volume":"30","author":"Cicconi","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102894_bib0029","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","article-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients","volume":"89","author":"Shen","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102894_bib0030","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcdb.2017.05.023","article-title":"ROS signalling in the biology of cancer","volume":"80","author":"Moloney","year":"2018","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.tranon.2026.102894_bib0031","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1038\/cddis.2013.273","article-title":"A ginseng metabolite, compound K, induces autophagy and apoptosis via generation of reactive oxygen species and activation of JNK in human colon cancer cells","volume":"4","author":"Kim","year":"2013","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.tranon.2026.102894_bib0032","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1742-4658.2009.07366.x","article-title":"ERK and cell death: mechanisms of ERK-induced cell death\u2013apoptosis, autophagy and senescence","volume":"277","author":"Cagnol","year":"2010","journal-title":"FEBS. J."},{"key":"10.1016\/j.tranon.2026.102894_bib0033","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1038\/s41388-020-1239-y","article-title":"Alterations of T-cell-mediated immunity in acute myeloid leukemia","volume":"39","author":"Li","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2026.102894_bib0034","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:27:30Z","timestamp":1787225250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326002317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"alternative-id":["S1936523326002317"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102894","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATO alleviates T-cell immunosuppression by inducing apoptosis-associated secretion of IL-2 in FLT3-ITD-mutated acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102894"}}